Eli Lilly: drug fails study for pancreatic cancer

(CercleFinance.com) - Eli Lilly has announced a failure in its Phase III Sequoia study evaluating pegilodecakin plus FOLFOX, compared to FOLFOX alone, in patients with metastatic pancreatic cancer whose disease had progressed during or following a first-line gemcitabine-containing regimen.


The pharmaceutical group states that the trial failed to achieve its primary endpoint of overall survival, and that side effects such as neutropenia, thrombocytopenia, fatigue and anemia were observed.

"Metastatic pancreatic cancer is one of the deadliest major cancers, with just three percent of patients in the U.S. living five years after the cancer is diagnosed," the Indianapolis based group said.


Copyright (c) 2019 CercleFinance.com. All rights reserved.